Exchange: NASDAQ·Updated 03:55 PM EDT
News
all
press releases
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?
Key PointsIovance's revenue rose 66% last quarter due to strong demand for Amtagvi...
Nasdaq News: Markets
More News
Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?
The mean of analysts' price targets for Iovance Biotherapeutics (IOVA) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake
Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.
Zacks
Why Did IOVA, REPL, ROKU Stocks Surge To 52-Week Highs Today?
The rally showed that investors are paying more attention to fast-growing healthcare and digital media companies.
Stocktwits
Why S&P 500, Dow Futures Are Slipping Overnight After Wall Street’s Second Straight Day In The Red
WTI crude crossed $78 as uncertainty over an Iran-Oman shipping agreement fueled inflation concerns.
Stocktwits
Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results
Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares are surging Thursday after the cancer therapy company shattered second-quarter expectations on both the top and bottom lines. Here's what you should know.read more...
Benzinga
Catalysts Put These Companies in the Spotlight
ClearOne (NASDAQ CLRO), NeOnc Technologies (NASDAQ:NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in today’s roundup.
24-7 Market News
IOVA Stock Heads For Best Day In Over 6 Years – Buyout Buzz Builds After Blowout Q2
The biotech company reported record second-quarter revenue fueled by strong sales of its cancer therapy Amtagvi.
Stocktwits
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of +35.29% and +13.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of +1,175.00% and +562.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.